<i>In vitro</i> and <i>in vivo</i> identification of clinically approved drugs that modify <i> <scp>ACE</scp> 2 </i> expression
The COVID-19 pandemic caused by SARS-CoV-2 has is a global health challenge. Angiotensin-converting enzyme 2 (ACE2) is the host receptor for SARS-CoV-2 entry. Recent studies have suggested that patients with hypertension and diabetes treated with ACE inhibitors (ACEIs) or angiotensin receptor blocke...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | ingelesa |
| Argitaratua: |
2020
|
| Sarrera elektronikoa: | https://doi.org/10.15252/msb.20209628 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|